

MATWIN 2009–2024

**15 years of oncology
innovation support**

MATWIN

MATURATION & ACCELERATING
TRANSLATION **WITH INDUSTRY**



subsidiary



TABLE OF CONTENTS

EDITORIALS 3

MATWIN ACTIONS 4

SUPPORTED PROJECTS 7-41

PARTNER TESTIMONIALS 42-57

ACKNOWLEDGEMENTS 58-59

MATWIN, the success story of Unicancer's very own innovation booster



Pr. Jean-Yves BLAY
Unicancer President



The last 20 years have been an extraordinary time for cancer research. On a nearly daily basis, we continue to witness major and fundamental scientific advances in every field: molecular biology, immunology, physics, mathematics, digital technology, etc. Our challenge? To transform these innovations as quickly as possible to ensure that every patient has an opportunity to benefit from them. Our MATWIN subsidiary is a vital and invaluable link in this chain, and safe to say, it is succeeding. Our acceleration program and major yearly events such as MEET2WIN have enabled our researchers to go further in their work and become entrepreneurs!

Within 15 years, this Unicancer subsidiary has received over 300 applications, evaluated and supported over 200 led by scientists and entrepreneurs. With more than 50 start-ups created and over 50 fundamental research projects transferred, the results speak for themselves. MATWIN-Maturation & Accelerating Translation With INdustry - has never been so aptly named.

We are proud of these results. Happy birthday MATWIN!



Pr. Fabrice BARLESI
MATWIN President
CEO of Gustave Roussy



We all know that France holds recognized excellence in basic research and clinical care of patients but is struggling to transform these assets into therapeutic and diagnostic solutions developed in France to the benefit of patients.

Pr Josy Reiffers, first President and founder of the MATWIN platform, was visionary fifteen years ago when launching this first French initiative to bring together research and industry ecosystems around oncology innovation! MATWIN has been a real catalyst to transform promising research ideas into products, to accelerate the maturation of start-ups, to connect pharma companies and investors to promising scientists and entrepreneurs, to develop an entrepreneurial cancer-focused culture! In the context of the ongoing structuring of the Paris Saclay Cancer Cluster, of which Gustave Roussy is one of the five founders, the MATWIN expertise and network is an essential asset!

Congrats to the very dedicated MATWIN team and happy birthday!

MATWIN PRESENTATION



MATWIN is a French open-innovation platform specifically dedicated to the support of innovation in oncology, fully owned subsidiary of Unicancer (the federation gathering the 18 French Comprehensive Cancer Centres).

For 15 years, MATWIN has been offering various actions (expertise, accelerator program, events, etc.) aiming to accelerate the development of innovative projects dedicated to the fight against cancer either

headed by scientists or entrepreneurs. These actions are based on a long-standing partnership with about 300 international stakeholders and companies keen on scouting innovative projects with a high industrial development potential in the field (partners in 2024, Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Exact Sciences, Insitro, MSD, Pierre Fabre, Pfizer, Roche, Sanofi, Takeda). MATWIN manages 3 main actions: the MATWIN accelerator program, a cancer-focused partnering event MEET2WIN, and the OncoSTART consortium which supports entrepreneurship in oncology.

1. MATWIN Accelerator Program

The MATWIN program is fully focused on supporting R&D innovative oncology projects headed by European scientists or entrepreneurs, offering them access to expertise, coaching/mentoring and showcase opportunities to enhance their development potential during a 3 or 6 month-support. The supported projects range from preclinical stage until early clinical stage (phase 1) with defined POC. It mainly concerns therapeutics, prognostic, theranostic, or diagnostic applications including AI tools. The program is supported by companies willing to develop partnerships in the field. More on www.matwin.fr

AMGEN

AstraZeneca

Boehringer
Ingelheim

Bristol Myers Squibb

**EXACT
SCIENCES**

GSK

insitro

MSD

Pfizer

Pierre Fabre

Roche

sanofi

Takeda

unicancer

From 2009, the MATWIN program has already reached a positive track record!

+300
supported
projects

+120
projects
presented to the
MATWIN Board

+50
already
transferred &
many clinical
trials ongoing!

+50
startups
created post
MATWIN
support

+300
jobs
created

2. MEET2WIN Oncology Partnering Convention



Each year MATWIN organises MEET2WIN, a European Partnering Convention entirely focused on oncology. The event gathers nearly 300 European and international attendees (pharmaceutical companies, biotechs, startups, researchers, clinicians, investors, support structures, etc.) and generates +1,000

face-to-face meetings to optimize collaboration opportunities in the oncology area. During 2 days, this European-scale event combines round tables presenting the latest insights in oncology, thematic workshops, spotlight sessions for startup or scientist' pitches, and many networking time. More on: www.meet2win.fr

9
MEET2WIN
events

+6000
B2B
meetings

+2600
participants

+200
projects'
pitches

Many
partnerships!




3. OncoSTART consortium

Created and coordinated by MATWIN, the OncoSTART consortium brings together 14 cancer-focused organisations willing to combine their strengths and network to support entrepreneurship in the oncology area! Together, they offer a whole range of actions related to training and support in order to develop and nurture an entrepreneurial culture around the fight against cancer in France. The actions of OncoSTART are open to all types of project owners (postgraduates, early-career researchers, aspiring and experienced entrepreneurs). The scheme operates as a toolbox, enabling tailored responses that cater for the specific needs of each project. More on www.oncostart.fr



Since OncoSTART was founded in 2021 :





SUPPORTED PROJECTS

Non exhaustive list

Category: Therapeutic
Creation date: 2022
Employees: 4
Location : Nantes, FRANCE



New innovative medical and pharmaceutical technologies in the field of the treatment of mucosal cancers and endometriosis

Abcely's mission is to develop new innovative medical and pharmaceutical technologies in the field of the treatment of mucosal cancers, thus offering patients in therapeutic impasse a new solution based on a brand-new concept of immunotherapy in cancerology. The concept developed by Abcely is based on the use of a new class of orally active therapeutic molecules (IgA). Abcely is involved in all phases of development, from the identification of compounds of biological origin as potential active ingredients to the demonstration of their activity in the human clinic.

Another very important aspect of Abcely' strategic development concerns the treatment of endometriosis. Endometriosis is a condition where tissue similar to the uterine lining grows outside the uterus, causing pelvic pain, painful menstruation and fertility problems. Abcely is engaged in an R&D program for a very innovative product (ABC-201), an orally active sIgA, directed against an (undisclosed) target involved in the early development of the disease.

Clinical indications : Mucosal cancers
(CRC, gastric, SCC) and endometriosis
Patent : 1
Funds raised : **2.4M €**

“Without MATWIN, the promoters of this project would have never met! MATWIN has been instrumental to create a favourable ecosystem for meetings between project leaders and entrepreneurs”



Jean-Marc HERBERT
CEO

LATEST NEWS

Public and private fundraising
(2.4M€ in 2023)

More on :

 @abcely

Category: Therapeutic
Creation date: 2013
Employees: 6
Location: Montferrier-sur-Lez, FRANCE



Towards the discovery of innovative cancer therapies

ERK proteins are kinases implicated in normal cells development which controls essential processes such as cell proliferation and survival. In most cancers, especially resistant-to-treatment cancers, ERK is overactivated leading to an uncontrolled proliferation of cancer cells and tumor development. Over the last few years, this protein has become a target of choice in oncology research programs. AGV Discovery identified a few years ago potent, selective and orally bioavailable inhibitors of the ERK kinases. The program represents for AGV Discovery the obvious proof of concept of the innovation strategy implemented within the company since its creation, by combining fragment based drug design techniques, close collaborations with the academic area and the experience of the team of researchers.

Clinical indications : MAPK
deregulated cancers
Clinical status : Clinical phase 1
Patents : 5
Funds raised : 1,5M €



Cédric BORIES
CEO

“MATWIN allowed the start-up to come into contact with large pharmaceutical laboratories, to significantly increase the visibility of the research program and to increase our network of contacts.”

LATEST NEWS

The program is in clinical development with IPSEN Pharma under a worldwide license agreement.

More on :

www.agv-discovery.com

Category: Therapeutic
Creation date: 2016
Employees: 8
Location: Paris, FRANCE



Biotech company developing a disruptive immunotherapy platform for the treatment of cancer based on synthetic Melanin as adjuvant.

ALTEVAX immunotherapy platform is based on synthetic melanin, a non-toxic and versatile biopolymer adjuvant, that can be combined with a wide range of antigenic peptides for vaccine formulations. Melanin is a particularly powerful adjuvant inducing an immune reaction similar to what occurs naturally in the human body. Our lead program, a therapeutic vaccine against Glioblastoma, is based on the tumor-associated antigen TERT and is ready to go clinic in Q3 2024 with all necessary steps initiated.

Clinical indications : Glioblastoma
Clinical status : Phase 1/2a trial of Glioblastoma
vaccin based on Melanin as adjuvant in Q3 2024
Patents : 4
Funds raised : **5,5M €**

“Our participation in MATWIN’s GROW program in 2024 has already been rewarding thanks to the high quality feedback and coaching we received in the preparation phase. The detailed and transparent feedback was a great tool to up our game.”



Paul VAN DER SCHUEREN
CEO

LATEST NEWS

2023 - AlteVax is awarded a 2,6 M€ package by BPI France

More on :

www.alteVax.com

Category: Therapeutic
Creation date: 2019
Number of employees: 10
Location: Reims, FRANCE



Biotech company developing a portfolio of proprietary first-in-class drug candidates targeting the tumor extracellular matrix (ECM) molecules.

Apmonia Therapeutics is a biotechnology company developing innovative therapeutic strategies against various cancers. Capitalizing on cutting-edge bioinformatics approaches, Apmonia Therapeutics targets so-called «matrix proteins» to fight tumors by reprogramming their microenvironment. The company's most advanced program is about to enter its first clinical trial in several advanced solid tumors. Apmonia Therapeutics' most advanced candidate and POC of the platform is a tumor microenvironment modulator named TAX2, a small peptide that blocks the interaction between Thrombospondin-1 (TSP-1) and CD47 receptors. This product will enter a Phase1/2a trial in 2024.

Clinical indications : Advanced solid tumors, including ovarian (primary indication), colorectal, pancreatic, glioblastoma.
Clinical status : Phase 1/2a first-in-human anticipated in 2024 (CTA clearance Q3.2024)
Patents : 3
Funds raised : 11M €



Albin JEANNE
CEO

“MATWIN support was key for the successful transfer of our technology from academia to start-up creation. It also helped over the last year to align our preclinical and early clinical development plan with industry expectations.”

LATEST NEWS

Successful completion of preclinical package (CMC & GLP Tox)-April 24: 2,7M€ non-dilutive financing from i-Nov Innovation Contest (Bpifrance) and PIA4-€20M Series A ongoing

More on :

www.apmonia-therapeutics.com

Category: Therapeutic
Creation date: 2019
Employees: 8
Location: Milladoiro, SPAIN



Developing a platform of new medicines based on quantum chemistry.

Cancers that either originate in the brain or spread into the brain from other sites have among the worst prognosis of all cancers. Treatment is limited by poor penetration of medicines into the brain and toxic side effects of treatments, meaning that large doses of treatment cannot be given. We are developing a new class of medicines that are extremely small molecules which can penetrate the brain, and act specifically on the mitochondria (energy generating centre) of cancer cells, leading to cancer cell death with few side effects. We believe that these treatments will revolutionise treatment of cancers in the brain.

Clinical indications: Glioblastoma multiforme
Patents: 6
Funds raised: 4M €

“Constructive, friendly advice from experts with deep experience. Helpful, non-confrontational and interesting! A very positive experience for us.”



Ross BRECKENRIDGE
CEO

LATEST NEWS

We have partnerships with the universities of Leuven, Tokyo, Oxford and Glasgow.

More on :

www.arjunatherapeutics.com

Category: Therapeutic
Creation date: 2022
Employees: 9
Location: Paris, FRANCE



First-in-class immunotherapies to treat cancer

Blue Bees Therapeutics develops first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, Department of Pharmacology and Immunoanalysis, CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Lead product, BB10X, activates immune cells and impacts growth of hot and cold tumors in mice, with therapeutic potential for multiple cancer indications.

Clinical indications: Solid tumors,
mainly carcinoma
Patents: 3
Funds raised: **2.0M €**



Philippe BERTHON
CEO

“Real and impactful contribution from mentors during the different stages of preparation before presenting our project to the MATWIN board.”

LATEST NEWS

Secured >2M€ in equity and grants, filed recently two new patents, presented lead product BB10x latest results at the AACR 2024

More on :

www.bbtx.fr

Category: Diagnostic / Biomarkers
Creation date : 2014
Employees: 11
Location: Clermont-Ferrand, FRANCE



Clinical-stage biotech company developing a new-generation of proteomic-driven immunotherapies, educating patient's immune system against tumor evolution and mechanisms of relapse.

Despite therapeutic advancements, fighting cancer requires new allies. Cancer cells can adapt themselves and express tumor antigens that hide from our immune system's surveillance. This mechanism leads to treatment failure of 90% of patients with solid tumors (16 million in 2022). Brenus Pharma is developing a pioneering discovery platform Stimulated-Tumor-Cell (STC) leading the path of a new generation of immunotherapies by mimicking patient's relapsing condition, in vitro. We anticipate how cancer will evolve tomorrow and train the patient's immune system to recognize and destroy tumors even as they change. We are building a strong portfolio in solid tumors, leveraging our patented STC platform, to change a paradigm in oncology.

Clinical indications: metastatic Colorectal Cancer (mCRC)
Patents: 2 patent families with 22 patents obtained
Funds raised : **6.8M €**
Clinical status: First in Human study (Phase IA/IIA) in 2024 for colorectal cancer patients in 9 international oncology centers.

"In 2021, Brenus received the support of the MATWIN Incubation Program, allowing us to present our project in front of key healthcare stakeholders and potential partners. As awardees, in 2022, we showcased improvements of the project and gained again insightful feedback from jury members (Scientific, clinical, production, IP...) with their advanced perspectives on the field. These interactions were crucial for refining our vision and strategy."



Paul BRAVETTI
CEO

LATEST NEWS

Positive preclinical results AACR2024 extrapolating human conditions with a robust efficacy and consistency on 4 different STC-1010 batches-Biotech of the year 2024, Healthtech Awards (France Biotech)
Winner of the «Innovations in Biotherapy and Bioproduction» call for proposals (France 2030) with ±5 M€ funding.

More on :

www.brenus-pharma.com

Category: Therapeutic
Creation date: 2020
Employees: 8 to 10
Location: Brno, CZECH REPUBLIC



Developing new therapeutic options for treatment-resistant tumors which increasingly becomes a problem in cancer therapy.

The mission of CasInvent Pharma is to develop new therapeutic options for treatment-resistant tumors which increasingly becomes a problem in cancer therapy. The company's therapeutic platform is based on proprietary, best-in-class, highly selective inhibitors of enzymes belonging to the Casein Kinase 1 (CK1) family. CK1 and its different isoforms are responsible for the regulation of key cellular mechanisms leading to resistance for targeted therapies. The founder's team has outstanding and long-term expertise in the research areas of CK1 biology and chemistry of kinase inhibitors. Currently, the company is in an advanced lead optimization stage and plans to enter IND-enabling studies in 2025 with focus on treatment-resistant Acute Myeloid Leukemia (AML) and solid tumor indications such as PDAC, TNBC, Melanoma or Prostate Cancer. CasInvent Pharma is seeking for a Series A financing round of 10 M€ to reach clinical proof of concept for CK1 compounds.

Clinical indications: PDAC, AML, Prostate Cancer, Melanoma, Breast (TNBC) cancer
Patents: 3
Funds raised: **3.6 M €** raised since 2020 in equity and grants



Alexander SCHEER
CEO

“Very good platform to get very constructive feedback and get connected with different partners including big pharma.”

LATEST NEWS

New PoC in vivo for Venotoclax resistant AML, Eurostars grant submitted

More on :

www.casinvent.com

Category: Therapeutic
Creation date: 2018
Employees: 5
Location: Nîmes, FRANCE



Take RNA Therapeutics to the next level: a new approach to gene modulation in cancer treatment

KRAS oncogene mutations play an essential role in the spread of more than 60% of cancers. Although they are major therapeutic target, there is no effective treatment against KRAS mutations, KRASG12C/G12D small molecule inhibitors KRAS inhibitors being limited by adaptive resistance. At DIVINCELL, we have developed a new therapeutic approach, DIV-TREX, which targets specifically KRAS mutant. DIV-TREX nano-vehicles are able to deliver gene editing scissors in the depths of the tumors, leading to a robust correction of KRAS oncogene mutations. DIV-TREX abolishes pancreatic, lung and colorectal tumors growth, associated with a strong tumor regression without inducing side toxic response and can be used in synergy with current cancer treatments. DIV-TREX constitutes a potent alternative strategy to overcome resistance associated to KRAS small molecule inhibitors. Considering its strong potency DIV-TREX paves the way to targeted and personalized therapies for the treatment of KRAS associated cancers.

Clinical indications: KRASG12 mutated cancers and resistance to KRASG12C and KRASG12D small molecule inhibitors

Patents: 3

Funds raised: 1.5M €

“MATWIN support has been an extremely fruitful experience for our company. MATWIN allowed us to focus and to give an international recognition to our project, to obtain essential feedback from KOLs, which was crucial for the development of our drug candidate.”



Gilles DIVITA
CEO

LATEST NEWS

Clinical trial is planned to start end of 2024 or early 2025 and IND-enabling studies

More on :

www.divinCELL-nanotechnology.fr

Category: Therapeutic
Creation date: 2020
Location: Paris, FRANCE



The best way to predict the future is to invent it

Findimmune is a Gustave Roussy's spin-off company developing anticancer and immune therapies, based in France and develops lead candidates for the treatment of cancer, based on immune stimulation for anticancer vaccination and on the conversion of unresponsive "cold" tumors into sensitive "hot" tumors as part of anti-cancer treatments. Findimmune also works on the delivery of innovative drugs in combination with immune checkpoint inhibitors. Findimmune benefits from a drug discovery research platform (UMR-S 1030 INSERM) in partnership with the Gustave Roussy Cancer Campus. It focuses on the identification of novel therapies dedicated to the manipulation of macrophage immune checkpoints that were recently discovered and patented for both anticancer and inflammatory diseases. We identify F1901 as a lead candidate for in situ cancer vaccination leading to cancer cells death through cannibalism, suppresses tumor growth, induces antitumor vaccination and enhances the efficacy of immunotherapy.

Clinical indications: Solid tumors

Clinical stage: The WOOF project will start Q3 2024 in canine oral tumors, a translational model of human tumors, and an opportunity to accelerate cash entry via veterinary medicine huge market.

Patents: 3

Funds raised: 1M€



Guillaume BRION
CEO

"Scientific members of the committee understand well our approach. Pharma members bring their expertise on business model and development strategy."

More on :

www.findimmune.com

LATEST NEWS

Strong partnership with TTO

Category: Diagnostic / Biomarkers
Creation date: 2020
Employees: 6
Location: Rouen, FRANCE



Offering cancer classification tests to improve the characterization of cancers through innovative approaches in molecular biology, AI and bioinformatics

Genexpath is designing next-generation diagnostic tests to better characterize cancers. We provide products based on an innovative and patented technology: LD-RT-PCR coupled with high-throughput sequencing that allows the amplification and quantification of a large number of markers of interest simultaneously (fusion transcripts or analysis of gene expression profiling). These products are optimized for patient diagnosis and are adapted to clinical research. They facilitate patient's stratification into clinical trials or detect markers for targeted therapies.

Patents: NC
Funds raised: **700K€** (equity)

« It was very interesting to get the opinion of experts about our products and to have the opportunity to pitch at Meet2Win in 2023. This allowed us to go further in our reflexion. It also offered a very important visibility and access to a very interessant network.»



Juliette RENAULD
CEO

LATEST NEWS

1 new test commercialized in 2023 and a new foundraising campain in progress

More on :

www.genexpath.com

Category: Therapeutic
Creation date: 2016
Employees: 5
Location: Angers, FRANCE



GC01.1 a game-changing anti-mitotic brain penetrant peptide for the treatment of glioblastoma and other aggressive cancers over-expressing β III-tubulin

Gliocure, a spin-off company of Angers and McGill Montreal universities, develops glioblastoma-specific drugs. Our lead product GC01.1, a new generation anti-tumour and neuroprotective peptide, is currently in the final stages of non regulatory preclinical development for the treatment of glioblastoma and other solid tumors overexpressing β -III tubulin. When supported by MATWIN at an academic stage, the project's objectives were to determine i) the tubulin isotype expressed in glioblastoma to which the AGP peptide is binding, and ii) the molecular receptor by which the AGP peptide penetrates in glioblastoma cells.

Clinical indications: Glioblastoma
Clinical status: Regulatory preclinical work planned in 2025 in order to obtain a first-in-human clinical trial authorization by mid-2026
Patent: 1
Funds raised: **3.5M €**



Louis-Marie BACHELOT
CEO

« MATWIN recognized the potential of our drug substance very early on, and the validation of the project by its international board was one of the key factors in setting up Gliocure few years later.»

LATEST NEWS

December 2023 - R&D collaboration with Institut de Cancérologie de l'Ouest SCAI laboratory in order to carry out a 3D monoculture screening of different types of breast cancer treated with GC01.1.

More on :

www.gliocure.com

Category: Diagnostic / Biomarkers
Creation date: 2016
Employees: 18
Location: Bilbao, SPAIN



Unveiling protein function in tissue for a spatial biology with true clinical value

QF-Pro® is a spatial biology platform for cancer diagnosis/prognosis at the molecular level, offering <10nm spatial resolution for precisely quantifying protein interactions and post-translational modifications in tumors. It contributes to improving personalized cancer treatments and drug effectiveness assessment. Its patented technology, featuring a novel assay for quantifying PD-1/PD-L1 complex formation, predicts immunology patient responses, aiding in the optimization of anti PD-1/PD-L1 therapies.

Clinical indications: Immune checkpoint inhibitor immunotherapies for NSCLC and other solid tumors
Clinical status: NC
Patents: 2
Funds raised: **8.5M €**

“The MATWIN program has been instrumental in the evolution of our business development. Their comprehensive support, which combined an expansive network with access to Key Opinion Leaders (KOLs) in our industry, significantly accelerated our project’s development. The expertise and insights provided by these KOLs have added immense value, guiding our strategic decisions and sharpening our competitive edge. Additionally, MATWIN’s ability to connect us with relevant stakeholders and potential partners has been a game-changer, opening doors that we might not have been able to on our own. In summary, MATWIN’s support has not just helped us grow; it has been a catalyst for innovation and expansion in our business.”



Fernando Aguirre
CEO

LATEST NEWS

Securing funding from investors, national and EU grants (notably EIC Accelerator) - Crucial clinical milestones reached - Publication in the Journal of Clinical Oncology - Strategic partnerships formed with top pharmaceutical companies

More on :

www.hawkbiosystems.com

Category: Therapeutic
Creation date: 2018
Employees: 5
Location: Lyon, FRANCE



Immunostimulants able to cure hard to treat tumors and metastatic patients

HEPHAISTOS-Pharma is a biotechnology company developing a new generation of cancer treatments based on the stimulation of patient's immune system. ONCO-Boost is the First-In-Class Immunostimulant injectable intravenous able to treat metastatic and hardly accessible cancer like Osteosarcoma. HEPHAISTOS-Pharma will bring Immunotherapy to the next level of efficiency by stimulating patients immune response and turning cold tumors into hot targets for our immune system.

Clinical indications: Osteosarcoma
colorectal cancer, Lymphoma
Patents: 2
Funds raised: **12.8M €**



Frederic CAROFF
CEO

“Very good visibility with the MATWIN award, great feedback from the coaches. Very useful feedback from the MATWIN board including pharma companies.”

LATEST NEWS

Seed fundraising with european VC and fund raising of 9 M€ with RHU project from ANR

More on :

www.hephaistos-pharma.fr

Category: Therapeutic
Creation date: 2009
Employees: 5
Location: Paris, FRANCE



Developing antibodies for treatment of cancers and inflammatory diseases

Inatherys is a biotechnology company that has now reached the clinical stage (treating patients with leukemia) and is at the heart of a wide network of subcontractors nationwide. The company possesses assets and expertise that are unique in the world in the design of monoclonal antibodies conjugated to a cytotoxic compound known as ADC. Inatherys is currently the only French biotechnology company to have an ADC in the clinical stage. Through its status as a research development and the management of its subcontractor network for production/logistics, Inatherys possesses a unique expertise in the design and production of ADCs, which paves the way for many new therapeutic molecules in the field of oncology.

Clinical indications: Acute Leukemias
Patents: 3
Funds raised: BPI H2020

“MATWIN allowed us to put several expertise both preclinical and clinical together.”



Pierre LAUNAY
CEO

LATEST NEWS

BPI H2020,
new fundraising obtained

More on :

www.inatherys.com

Category: Therapeutic
Creation date: 2021
Employees: 1
Location: Tours, FRANCE



First- or best-in-class ADCs for cancer patients with unmet medical needs

MIO is a French biotech company composed of a team of experts in ADC and oncology, which has developed an expertise in the field of ADC. Its objective is to develop new precision therapies, best in class or first in class, for cancer patients with unmet medical needs, in orphan diseases and broader oncology indications. The first product in its pipeline is ADCITMER®, an immunoconjugate targeting CD56, a target investigated up to phase II and incorporating a proprietary and robust conjugation platform. ADCITMER® has demonstrated superior activity in preclinical in vitro and in vivo models and an improved safety profile compared to the reference.

Clinical indications: CD56+ cancers with first trial in pantumor + cohort extension in Merkel Cell Carcinoma and Small cell lung cancer
Patents: 3



Audrey DESGRANGES
CEO

“It is a great experience to present the project in front of the MATWIN panel of experts. Indeed, the questions and comments are highly relevant and allows to better present / defend the project with the aim to raise funds. The written feedback is also very informative and provide precise guidance.”

LATEST NEWS

More on :

www.mcsaf.fr

Very positive scientific advice (Paul Ehrlich Institute) on preclinical data, development plan and clinical synopsis

Category: Therapeutic
Creation date: 2018
Employees: 5
Location: Paris, FRANCE



Redefining functional biology cell by cell: Minos Biosciences' breakthrough solution for research and development in oncology & immuno-oncology

Minos Biosciences, a spin-off of the ESPCI Paris - PSL, develops a revolutionary solution for the analysis of single cells or cell-cell interactions at high throughput, allowing a direct coupling between dynamic functional assays and omic analyses, at single-cell resolution. This unique approach will pave the way for the discovery of new therapeutic targets or biomarkers, and the development of new therapeutic approaches, notably cell therapies.

Patents: 5
Funds raised: **4.8M €**

“For Minos, taking part in the MATWIN “Start” accelerator programme in 2024 is an exceptional opportunity to gain access to the business and scientific expertise available within the consortium and its international board expertise. We already had great feedback and gained precious insights from the various coaching sessions that we have attended so far!”



Fergus MC KENZIE
CEO

LATEST NEWS

2024 Laureate of the Start in America / NETVA Program

More on :

www.minos.bio

Category: Therapeutic
Creation date: 2019
Number of employees: 5
Location: Geneva, SWITZERLAND



Improving the performance of T cell therapies using the novel small molecule MITO-66

MPC Therapeutics has developed a high-value reagent to enhance the performance of CAR T cell therapies against cancer. Our clinical candidate, MITO-66, is added in the culture medium of CAR T cells where it plays a pivotal role to increase the proportion of Memory Stem Cells (TSCM) which are associated with better clinical outcomes, and increase the metabolic fitness of the entire CAR T cell population, enabling them to fight cancer cells more vigorously. The mechanism of action has been published in Cell Metabolism (Wenes et al, 2022) and involves a metabolic and epigenetic reprogramming. In several preclinical models, involving solid and blood cancers in humanized mice, these enhancements result in more effective and long-lasting therapeutic outcomes. Compared to standard CART therapy, which cures 40% of mice, MITO-66 conditioning enables CAR T cells to cure 100% of mice-bearing human leukemia cells, drastically improves anti-tumor effects in hard-to-treat solid tumors and protects mice better from cancer relapse.

Patents: 2

Funds raised: Seed round of **1,2M CHF**



Raphaël MARTINO
CEO

“Winning several awards at MATWIN was very motivating for the team and boosted our credibility, attracting valuable attention, partnerships, and opportunities.”

LATEST NEWS

As of April 2024, already 10 MTAs signed with major pharmaceutical companies, biotechs and research organizations to enable CAR-T manufacturers to test MITO-66 in their manufacturing processes + 12 collaborations in progress under NDA. Several partners testing MITO-66 in other cell types (NK, iPSCs, TILS, and TCRs).

More on :

www.mpc-therapeutics.com

Category: Diagnostic / Biomarkers
Created since: 2014
Number of employees: 19
Location: Lausanne, SWITZERLAND



The Novigenix AI-driven RNA platform offers precise and predictive immune response profiling for better patient outcomes

Unleashing the immune system against tumours is an effective therapeutic strategy. Although these novel treatments have revolutionised the clinical management of various malignancies, only a subset of patients effectively benefit long-term. In this context, precise biomarkers predicting therapy clinical benefit and adverse immune side-effects are urgently needed to guide oncologists and to optimize drug development and approval. Our goal is the development of pan-cancer therapy prediction models that can foresee clinical benefit to therapy, toxicity and mode of action.

Patents: 5
Funds raised: 20M €

“Being involved in the 2024 MATWIN “Grow” accelerator program, we’ve already received a very useful feedback and excellent comments during the coaching session with KOLs and experts.”



Brian HASHEMI
CEO

LATEST NEWS

Company closed round B of investment in 2022

More on :

www.novigenix.com

Category: Therapeutic
Created since: 2017
Location: Strasbourg, FRANCE



Innovative personalized immunotherapy based on synthetic DNA formulation and AI

We are a startup developing a proprietary immunotherapy platform dedicated to personalized cancer treatment, based on the disruptive technology of synthetic DNA and advanced algorithms. We claim to be able to bring this type of treatment to patients in a shortened timeframe (6-7 weeks), compatible with clinical management and at an acceptable cost for our healthcare systems. Since its creation, OdimmA-therapeutics has accumulated proof of concept with competitive preclinical results and has built a qualified team thanks to which we are now on the eve of the first in man clinical trial (summer 2024).

Clinical status: Phase I
in Colorectal carcinoma
Patents: 2
Funds raised: 5M €



Pascale BALDUCCHI
CEO

“MATWIN support has been very important to raise awareness around our project and to interact with experts and decision makers of the field, scientists and investors.”

More on

www.odimma-therapeutics.com

LATEST NEWS

Secure supply chain - Toxicology study - GMP manufacturing process

Category: Medical device
 Creation date: 2020
 Employees: 22
 Location: Paris, FRANCE



Automated organoids screening technology for drug discovery

Okomera, a Paris-based biotech startup, is pioneering an advanced organoid screening technology for drug discovery and efficacy testing. The innovative platform comprises a compact bench-top device, microfluidic chips, and Hemera—an AI-powered analysis software. Designed for automation, the technology simplifies organoid screening, making it accessible to users of varying expertise levels. The technology consists of a bench top device (that fits under a laminar flow hood), microfluidic chips and Hemera - an AI-powered analysis software. This high-throughput technology allows screening of up to 100 conditions per batch, with rapid results achievable within a week. The miniaturized approach eliminates the need for cell expansion, ensuring quick and efficient screening.

Patents: 5

Funds raised: >12M €

“The MATWIN support enables networking opportunities with KOLs in pharma and valuable insights in drug development pipelines and where our technology adds value in the process.

We also look forward to potential co-development projects within the scope of drug development initiated at MEET2WIN.”



Sidarth RADJOU
CEO

LATEST NEWS

RHU Organomic grant (9M€) awarded 2022, industrial partner together with Gustave Roussy, Institut Pasteur, Central Supelec, Inserm, AstraZeneca and ORAKL Oncology - Eurostars (0.4M€) granted 2024 to develop a T-cell potency assay together with Neogap AB (Sweden) - Collaboration on Drug screening of Pediatric Neuroblastoma with Institut Curie - Cancer Research UK: collaboration on glioblastoma and irradiation -Subsidiary creation in the US 2024

More on

www.okomera.com

Category: Therapeutic
Creation date: 2020
Employees: 4
Location: Stockholm, SWEDEN



Creating novel therapeutics for cancer patients

One-carbon Therapeutics AB is developing new drugs that can efficiently attack cancer cells but not healthy cells, resulting in fewer side effects for the patients. We are developing novel small molecule inhibitor made using cutting-edge science that targets validated cancer-specific proteins MTHFD1&2. Our goal is to create innovative therapies for difficult-to-treat cancer patients with few existing treatment alternatives, including colon, lung, and haematological cancers.

Clinical indications: Solid tumors, colorectal and lung

Patents: 2 patent families with 22 patents obtained WW

Funds raised: 1M €



Ana Slipicevic
CEO

“Very good program with valuable networking possibility and game-changing feedback from major big pharmaceutical companies.”

LATEST NEWS

GLP studies ongoing, Important KOLs recruited to SAB, additional funding secured from existing investors. Planned start trial 2025.

More on

www.one-carbon.com

Category: Therapeutic
Creation date: 2023
Employees: 6
Location: Villejuif, FRANCE



Best-in-class biology with high-quality patient data to transform oncology drug development.

Cancer complexity and heterogeneity leads to a 96% failure rate of drug candidates in clinical trials and jeopardize the promise of personalized oncology. Orakl Oncology's ambition is to bring back patient's tumor at the center of oncology drug development. By leveraging a collection of patient tumor avatars, they predict how each patient will respond to future drugs. Orakl Oncology is a techbio platform that bridges best-in-class biology with deep clinical data and machine learning to efficiently discover and optimize new treatments for the right patients. Thanks to their technology, Orakl Oncology works with drug developers to bring better drugs to patients, faster.

Clinical indications: All solid tumors, starting by colorectal cancer
Clinical status: The clinical trial ORGANOTREAT started in 2022 with >1000 patients, in different phases assessing the role of organoid-based drug testing for precision medicine in any type of solid tumor.
Patents: 5
Funds raised: 4.8M €



Fanny JAULIN
CEO

“MATWIN and Meet2win network, along with advisors from the pharmaceutical and biotech sectors, provide invaluable long-term support. This ongoing collaboration fosters potential partnerships and expedites our company's development. I wholeheartedly endorse participation in MATWIN as its benefits are truly immeasurable until experienced firsthand.”

LATEST NEWS

Jan/Feb 2023: start-up creation and signature of license agreements with Gustave Roussy.
-Summer 2023: laureates from 1.7M€ grants. -Sept 2023: 3M€ equity fundraising.-
Dec 2023: publication of Cartry et al. in J Exp Clin Cancer Res & Boilève et al. under review.-March 2024 : Hello Tomorrow Global Challenge finalists.

More on

www.orakl-oncology.com

Category : Therapeutic
Creation date : 2014
Employees : 43
Location: Liège, BELGIUM



Clinical-stage biotech company that develops an innovative class of cancer vaccines for cancers, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells.

Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells (PDC*line). PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC*line Pharma is now focused on the development of PDC*lung01, its candidate for Non-Small-Cell Lung Cancer (NSCLC), currently in phase I/II trials, and PDC*neo with neoantigens, in preclinical development.

Clinical indications: Non Small Cell Lung Cancer (lead asset) and colorectal cancer

Clinical status: Lead asset is PDC*lung01, a candidate for Non-Small-Cell Lung Cancer (NSCLC), currently in phase I/II trials on 67 patients

Funds raised: 61M €



Eric HALIOUA
CEO

“Extremely valuable advice and coaching by MATWIN experts and Industrial Board, even for a biotech company. It has increased our industry contacts and enabled us to get feedback from real experts, similar to a due diligence role!”

LATEST NEWS

October 2023, closing of enrolment of patients in PDC-LUNG-101 phase I/II clinical trial

April 2024, oral presentation of interim clinical results of our therapeutic cancer vaccine PDC*lung01 in patients with stage IV Non-small Cell Lung Cancer at AACR 2024.

More on

www.pdc-line-pharma.com

Category: Therapeutic
Creation date: 2024
Employees: 6
Location: Paris, FRANCE



Biotech specialized in therapeutic peptides targeting CD47 via a novel agonist mechanism of action.


PepKon is a French biotech developing first-in-class peptides for oncology, with over ten years' experience in academic research. These thrombospondin-1 mimics are CD47 agonists. They are selective for cancer cells and trigger immunogenic, calcium-dependent cell death. They are suitable for large-scale production and possess excellent physico-chemical properties. PKT16 is a drug candidate for several leukemias and solid tumors, with an initial focus on chronic lymphocytic leukemia, a chronic and incurable disease. PepKon aims to start a clinical trial by the end of 2025.

Clinical indications: Chronic Lymphocytic Leukemia

Patents: 2

Funds raised: 4,6M €

“Great expertise from MATWIN’s coaches and experts: company strategy, medical strategy, preclinical development, pitch method... And extremely precious feedback from the pharma representatives!”



Jonathan LEVY
CEO

LATEST NEWS

I-Lab 2023. Seed in november
2023. Innov'up Leader PIA 2024.

More on

www.pepkon.com

Category: Therapeutic
 Creation date: 2014
 Employees: 9
 Location: Montpellier, FRANCE



Disruptive cancer and fibrosis treatments, by targeting the aberrant N-glycosylation of pathological cells with NCEs.

Our NCEs are inhibitors of GnT-V, a N-glycosylation enzyme and intracellular target, sole responsible for the formation of tetra-antennary glycans at the surface of pathological cells. By removing this complex glycocalyx, the treatment as a monotherapy induces a pleiotropic effect associating direct effects on growth, proliferation, and migration to a restauration of an immune response. With a confirmed excellent safety profile, it can also facilitate the access to masked membranar receptors for other drugs.

Clinical indications: Solid tumors, fibrosis

Clinical status: The PhAST trial, an adaptive First-In-Human for patient with Advanced Solid Tumors is currently on-going in FRance and Italy (2022-2025)

Patents: > 55

Funds raised: 18M € (equity & non-dilutive)



Karine CHORRO
 CEO

“At the maturation step, MATWIN provided highly significant support, mainly through feedback from pharma representatives within the Board and advices from KOLs, to enable the transformation of a research program into a start-up, by highlighting strengths and weaknesses, key milestones, and key skills to move forward.”

LATEST NEWS

In 2023: deal concluded with Taiho Pharmaceuticals; awarded in the I-Nov competition – 9th wave (France 2030); finalist of the Trophées INPI 2023 in the Collaborative Research category – in 2022: entering clinical development – in 2020: series-A with international VCs.

More on

www.phostin.com

Category: Diagnostic / Biomarkers
Creation date: 2022
Employees: 9
Location: Paris, FRANCE



Developing the first-ever radiological foundation model, as the "GPT" of radiology

Raidium is developing the first foundation models of machine learning dedicated to radiology, akin to the architecture of GPT and ChatGPT, with an initial intended use in clinical trials. The objective of this project is to build a dedicated subproduct for oncological imaging biomarkers. Innovation & Differentiation: Our study introduces the enhanced utility of self-supervised and interactive 3D segmentation of lesions on 3D imaging. The objective is to diminish both inter-reader and intra-reader variability of the standard biomarker used in trials (RECIST measurements), before going beyond with 3D-segmentation based imaging biomarkers.

Clinical indications: Solid cancers
Patents: 1
Funds raised: **1.2M €**

"MATWIN rigorously challenged our project from both business and research perspectives, provided us with opportunities to pitch directly to top-level researchers and pharma representatives, and played a crucial role in identifying and connecting us with potential prospects in oncology."



Paul HERENT
CEO

LATEST NEWS

ASCO abstract accepted in may 2024 on the first results showing the added value of a Promptable foundation model for automatic whole body RECIST measurement.

More on

www.raidium.eu

Category: Therapeutic
Creation date: 2023
Employees: 2
Location: Grenoble, FRANCE

ReACT
THERAPEUTICS

ReACT Therapeutics' invention will stop cancer patients dying by potentially inhibiting the primary mechanism causing treatment resistance.

ReACT Therapeutics invented a potent and specific drug class to inhibit Breast Cancer Resistance Protein (BCRP), a transporter causing drug resistance. Our lead drug, ValOMé, is an effective, selective, non-toxic, and easy to produce preclinical drug. Combining ValOMé with known resistant anticancer drugs could restore cancer treatment efficacy and induce cancer remission. We can impact across 40 anticancer drugs, BCRP substrates, used to treat 14 cancer indications.

Clinical indications: Resistant cancer
Patent: 1
Funds raised: **550k €**



Emile ROUSSEL
CEO

“The 2024 MATWIN START program has allowed us to mature our project and challenge our vision on our preclinical development.”

LATEST NEWS

New strategic collaborations (Brazil, USA, France) - First round of fundraise from Business Angels (on going) - Additional preclinical validations on mammary and pancreatic cell lines - TOP100 Deeptech Connect, TOP40 Start Innovation Business Award, TOP10 Onco Startup Summit

More on

www.react-therapeutics.com

Category: Therapeutic
Creation date: 2017 (operations started in 2019)
Employees: 35
Location: Paris, FRANCE



Pioneering thymus-empowered T-cell progenitor therapy platform to fight cancer and infection

Smart Immune is a clinical-stage French biotechnology company developing ProTcell, a thymus-empowered T cell progenitor platform to rapidly re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies. The company aims to radically improve outcomes for patients in hematology and immune-oncology. Smart Immune has ongoing collaborations with leading institutions in the US and Europe. SMART101 is in Phase I/II clinical trials in cancer patients with AML and ALL, in SCID in the EU and the US. Smart Immune is also developing therapies using gene-modified T cell progenitors through its ProTcell platform to provide targeted treatments like off-the-shelf CAR T. The Company is headquartered in Paris, France.


Clinical indications: post allo-HSCT hematology (blood cancers and primary immune deficiencies) and in association with cancer treatments (BiTES and ICI)

Patents: 2 and additional patents filed

Funds raised: 23M €

Clinical status: SMART101 is evaluated in several Phase I/II trials in Europe and the US; very encouraging preliminary data

“With MATWIN, we benefited from top-quality coaching, in every strategic aspect, including pitch training, flagship project selection, and anticipation of development stages. The working sessions familiarized us with the expectations of an audience of investors and potential industrial partners. What we present today better enhances the potential of our platform, both for patients and for future partners.”



Karine ROSSIGNOL
CEO

LATEST NEWS

The first adult leukemia patients of its ReSET-02 haplo-PTCy trial were treated in September 2023 - New trials are being prepared, to be launched in the EU and the US - February 2024, Smart Immune appointed new key members to its Board of directors.

More on

www.smart-immune.com

Category: Therapeutic
Creation date: 2014
Employees: 8
Location: Lyon, FRANCE



Targeting the multidrug transporter Patched increases chemotherapy efficiency First-in-class anticancer

Step Pharma's lead drug STP938 is the first in a novel class of oral nucleotide synthesis inhibitors targeting cytidine triphosphate synthase 1 (CTPS1). The discovery of CTPS1 as a potential target for cancer was based on studies of humans with a CTPS1 deficiency providing genetic evidence that CTPS1 inhibition could be used to treat lymphoproliferative cancers. STP938 is currently in a Phase I/II clinical study in Lymphoma patients. In addition, a solid tumour study is planned to start in 2024 using a biomarker to select patients sensitive to CTPS1 inhibition.

Clinical indications: Haematological Malignancies (T and B cell Lymphoma) and ovarian, bladder, lung, eosophageal tumours

Clinical Stages: Yes, A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas (NCT05463263) and A Phase 1 Study of STP938 for Adult Subjects With Advanced Solid Tumours (NCT06297525)

Patents: 15

Funds raised: 52M €



Andrew PARKER
CEO

“Winning several awards at MATWIN was motivating for the team and provided us credibility among our future partners.”

LATEST NEWS

Signs of clinical activity already demonstrated and report the full dose escalation data soon - We will start a Phase I study in 3Q24 initially focused on ovarian cancer and then expand into other tumour types - Nominee in the best start up category for the Prix Galien in 2023.

More on

www.step-ph.com

Category: Therapeutic
Creation date: 2014
Employees: 6
Location: Strasbourg, FRANCE



Developing safer and more efficacious ADC treatments for cancer patients

Syndivia, a biotechnology company specializing in the discovery and early development of ADCs, is at the helm of this endeavor. We have an extensive intellectual property portfolio that includes DAR1 ADCs and a unique conjugation technology platform essential for manufacturing these advanced ADCs. Our past successes include the development and out-licensing of an ADC currently in phase I/IIa clinical trials—a collaboration initially forged during MATWIN 2014. By successfully creating this ADC, we aim not only to address the unmet medical needs in mCRPC but also to extend the application of our DAR1 technology to other solid tumors. This will have the potential to revolutionize the treatment landscape in oncology and lead to novel antibody-drug conjugates with enhanced properties and therapeutic index.

Clinical indications: AML, mCRPC, NSCLC
Patents: 5
Funds raised: **5M €**
Clinical status: Inatherys conducts
Phase 1/2a using the technology supported by MATWIN

“MATWIN enabled Syndivia to secure its first deal on its proprietary ADC platform.”



Sasha KONIEV
CEO

LATEST NEWS

Ongoing Phase 1/2a (product using Syndivia's proprietary technology), creation of Auricula Biosciences (regulatory toxicology & Phase 1/2a financed by TVM Capital)

More on

www.syndivia.com

Category: Medical Device
Creation date: 2015
Employees: 2
Location: Saint-Denis, LA REUNION



Metallic nanoparticles obtained by green chemistry for oncological applications: gold and hybrid core shell nanoparticles

Torskale develops metallic nanoparticles obtained by green chemistry for the physical destruction of tumor cells. Gold nanoparticles activated by near infrared laser thermally destroy skin tumors, such as basal cell carcinomas (BCC) or melanoma. Gold nanoparticles are obtained with medicinal plant extracts. Cell internalization was studied in collaboration with Institut Pasteur Paris. Iron oxide nanoparticles for medical imaging (MRI) or hybrid core shell iron oxide gold nanoparticles as radioenhancer for deeper organ cancers such as pancreatic, lung cancer. Hybrid nanoparticles are obtained by sonochemistry in collaboration with ICSM CNRS UMR5257.

Clinical indications: Skin cancers with gold nanoparticles.
Lung and pancreatic cancers for hybrid core shell gold iron oxide nanoparticles
Patents: 3
Funds raised: 2M € as non dilutive funds



Anne-Laure MOREL
CEO

“MATWIN is a fantastic networking opportunity to find industrial partners for the co-development of the technology and promote our gold nanoparticles for diagnostic or nanovectorization applications.”

LATEST NEWS

Scientific advice from ANSM, set up of QMS 13485 - POC preclinical efficacy on larger tumors (500mm³) of carcinoma basal cell - novel synthesis of hybrid nanoparticles for deep organ applications - website commercial platform for gold nanoparticles.

More on

www.torskale.com

Category: Therapeutic
 Institutions: Inserm-Université de
 Rennes-
 Centre de lutte contre le cancer
 Eugène-Marquis
 TTO support: Inserm Transfert
 Location: Rennes, FRANCE

Inserm

La science pour la santé
 From science to health




Developing safer and more efficacious ADC treatments for cancer patients

Endoplasmic Reticulum stress signaling and its sensor IRE1 have been identified as potential therapeutic targets in cancer. As such several IRE1 inhibitors were developed of which some are currently in clinical trials. However, those inhibitors are inefficient for treating brain cancers. Herein we have identified a novel family of IRE1 inhibitor able to cross the BBB to treat primary (glioblastoma) or metastatic (breast) brain cancers alone or as adjuvant.

Clinical indications: Brain tumors
 (primary or metastatic)
 Patents: 3
 Funds raised: **332k €**

**“Strong added value in better defining
 and valorize the project towards
 anticancer drug development and
 networking.”**



Eric CHEVET
 Research Director

LATEST NEWS

We have identified the best lead of the family based on preclinical (efficacy) studies, which is currently being further improved (based on crystal structure)

More on

Pelizzari-Raymundo et al. “A novel IRE1 kinase inhibitor for adjuvant glioblastoma treatment.”
 iScience, 2023

Obacz et al. “IRE1 endoribonuclease signaling promotes myeloid cell infiltration in glioblastoma.”
 Neuro-oncology, 2023

Category: Therapeutic

Creation date: planned for the end 2024

Employees: 9

Institutions: CNRS and Université Côte d'Azur

TTO support: CNRS Innovation

Location: Nice, FRANCE



Targeting the multidrug transporter Patched increases chemotherapy efficiency First-in-class anticancer

To combat cancer resistance to treatment, the main cause of therapeutic failure, Patched Therapeutics intends to develop drugs complementary to existing chemotherapies and targeted therapies, targeting the Hedgehog receptor Patched involved in chemotherapy efflux and cancer cell resistance. This new therapeutic strategy will improve the efficacy of anti-cancer treatments against resistant cancer cells, and increase patients' chances of survival.

Clinical indications: Melanoma and all cancers expressing Patched
 Patents: 1 in 2025 and 1 currently being drafted
 Funds raised: **720k €**



Isabelle Mus-Veteau
 Research Director

“We benefited from coaching to prepare our presentation to the Matwin board. The feedback we received from representatives of pharmaceutical companies and VCs was very constructive and useful for the development of our project.”

LATEST NEWS

We have shown that a molecule produced by a marine sponge inhibits the drug efflux activity of Patched and enhances the efficacy of the BRAFV600E kinase inhibitor vemurafenib against BRAF-mutated melanoma cells. We have synthesized and optimized this molecule to develop a drug candidate. Recently, we established a partnership with Technofounders to create the start-up Patched Therapeutics.

More on

<https://bit.ly/PatchedTarget>

The background features a gradient of red tones. On the left and right sides, there are decorative elements consisting of multiple thin, parallel, wavy lines that create a sense of motion and depth. On the right side, there is also a section with a fine grid pattern, possibly representing a data visualization or a technical theme.

PARTNER TESTIMONIALS



Angels Sante



“MEET2WIN is an excellent event to promote early connections in oncology innovation. The scientific and investment experts present make it a must attend type of event for any oncology start-up. Angels Santé is present every year as a jury member of the OUI Investors’ panel, mentor within the MATWIN Accelerator program and enthusiastic partner! Last but not least... Angels Sante is also very proud to co-organize with MATWIN the “Onco Startup Summit” an event dedicated to oncology startups, as part of the IFODS congress.”

Caroline SAÏ
Director



www.angelssante.fr



@angelssante



Bristol Myers Squibb



“MATWIN performs a vital role linking the pharma industry with emerging biotechnology organisations. Importantly, the quality of the program continues to improve year on year!”

James CARMICHAEL
VP Integrative Sciences/R&D Global



“The MATWIN activities are a unique opportunity to get a yearly overview of preclinic research in oncology across France and Europe, embracing the diversity of components such as academia, start-ups and other stakeholders. It is also an amazing way to showcase French research and innovation at BMS Headquarter! Happy birthday MATWIN and congrats for the tremendous contribution over the last 15 years to structure the oncology ecosystem!”

Jérôme GARNIER
Oncology Hematology
BU Executive Director
France

 www.bms.com

 [@bristol-myers-squibb](https://www.linkedin.com/company/bristol-myers-squibb)

 [@bmsnews](https://twitter.com/bmsnews)

 [@BristolMyersSquibb](https://www.youtube.com/channel/UCBristolMyersSquibb)

 [@Bristol Myers Squibb](https://www.facebook.com/BristolMyersSquibb)



Boehringer Ingelheim



“MATWIN provides an excellent opportunity to gain access to the French as well as now Europe wide biotech innovation space. The way the program works, with a selection panel, coaching sessions and eventual review by an expert panel, gives companies the opportunities to develop, become more competitive and develop valuable business relations.”

Mark PEARSON
VP Cancer Pharmacology
MATWIN Board member

 www.boehringer-ingelheim.com/fr

 @boehringer-ingelheim

 @Boehringer

 @boehringeringelheim



Canceropôle SUD



“Canceropôle SUD has been highly involved in the different MATWIN actions ; the MATWIN accelerating program, the MEET2WIN networking event and more recently the OncoSTART consortium. Today, this network is demonstrating its value by enabling its members, who share the same ambition of supporting researchers in their efforts to valorize their research and promoting entrepreneurship, to pool their strengths and offer joint events and trainings throughout the territory.”

Johanna KABADANIAN
Director



www.canceropole-paca.com



[@canceropôle-paca](https://www.linkedin.com/company/canceropole-paca)



[@CanceropolePACA](https://twitter.com/CanceropolePACA)



[@Canceropôle Provence-Alpes-Côte d'Azur](https://www.facebook.com/CanceropoleProvenceAlpesCoteAzur)



[@canceropoleprovence-alpes-3729](https://www.youtube.com/channel/UC...)

**EORTC***The future of cancer therapy*

“The MATWIN International board is the only committee of its kind in the world! It offers very interactive meetings where academics, industries and investors meet and exchange. A unique opportunity to fully evaluate all aspect of a project and assess the full potential. Bravo to MATWIN for such a great initiative to be continued!”

Jean-Pierre BIZZARI
Chairman New Drug Advisory Committee EORTC
MATWIN Board member

 www.eortc.org @eortc @EORTC @EORTCCHQ @EORTC @eortc_org



Expertise-Patient



“MEET2WIN was an opportunity for me to make the voice of patients heard and to demonstrate the interest of collaborating with them when developing a project aimed at improving the patient’s care and health pathway. It was also an opportunity for me to meet some very interesting people, which led to some great collaborations with start-ups. In addition, as a speaker at the OncoSTART Entrepreneurship School on patient partnership, I welcome this innovative initiative designed to help young entrepreneurs involved in oncology. Whatever the stage of maturity, MATWIN is able to provide support to help innovators speed up access to the best treatments for patients.”

Françoise SELLIN
President and founder



www.expertise-patient.care



@françoise-sellin-58166b12



Foundation Fournier-Majoie



“For the last 6 years now, the Foundation Fournier Majoie, a Belgium foundation dedicated to empowering entrepreneurs to crush cancer, has been partnering with MATWIN, a fantastic organisation that unleashes the potential of promising oncology projects not only in France but also in Europe. In six years, the Foundation has managed to study and invest in three startups supported by MATWIN (Apmonia Therapeutics, Mablink, Hephaïstos) after presenting their project in front of the MATWIN International Board and/or the OUI Oncology panel of investors specialised in investing at a seed-series A stage. A very concrete and game-changing partnership for the supported entrepreneurs! ”

Jerome MAJOIE
CEO



www.fournier-majoie.org



[@fondation-fournier-majoie](https://www.linkedin.com/company/fondation-fournier-majoie)



[@Fondation Fournier-Majoie](https://www.facebook.com/Fondation-Fournier-Majoie)

france biotech

France Biotech

biotech | medtech | e-santé | IA

LES ENTREPRENEURS DE LA HEALTHTECH



“A very good and unique level of oncology expertise within the MATWIN cluster which represents a fantastic added value for companies willing to validate their development route and accelerate their market access. A very nice partnership that France Biotech is looking forward to pursuing to help spread the entrepreneurial spirit and support companies within the oncology area.”

Chloé EVANS
Deputy Director General

 www.france-biotech.fr

 [@france-biotech](https://www.linkedin.com/company/france-biotech)

 [@FranceBiotech](https://twitter.com/FranceBiotech)

 [@francebiotech6810](https://www.youtube.com/channel/UC...)



Medicen Paris Region



“MATWIN is an experienced partner who has successfully developed a unique positioning in the field of oncology with a unifying approach to the various stakeholders from academic to industrial. The business meetings MEET2WIN are notably of very high quality and have allowed both to highlight promising companies and to stimulate sustainable business partnerships between SMEs and large groups.”

Julien ETTERPSERGER
General Manager



www.medicen.org



@ medicen-paris-region



@Pole_Medicen



@PoleMedicen

**Pfizer**

“Being a MATWIN Board member for 4 years, I highly enjoyed having the chance to evaluate and discuss in depth and in a unique peer review - consisting of representatives from pharma, academic medical centers, and cancer research institutions - proposals from academic groups, start-ups and biotech companies for novel therapeutics and diagnostics approaches. The impressive and long list of French and European biotechs that participated in the Accelerator Program in the past and received support from MATWIN in the form of coaching, as well as exposure to the MATWIN Board Members from Academia and pharma industry, as well as VCs clearly underlines the success of MATWIN. Moreover, the MEET2WIN event provides an excellent opportunity for networking and meeting with start-ups, early-stage and mature biotech companies with a focus on cancer therapeutics, diagnostics/ AI, as well as TTOs representing French research and academic institutions for initiating discussions around potential collaborations and partnering.”

Anette SOMMER

Senior Director, Emerging
Science & Innovation-Lead
Oncology Europe
Former MATWIN Board
member



www.pfizer.fr



[@pfizer](https://www.linkedin.com/company/pfizer)



[@Pfizer_France](https://twitter.com/Pfizer_France)



[@PfizerFrance](https://www.youtube.com/channel/UC...)

Paris Saclay Cancer Cluster



“MATWIN has succeeded in establishing the MEET2WIN congress as one of the major annual meetings for innovation in oncology in France, which brings together players from the entire innovation chain, including a network of world-class experts to support the most promising projects. As a close partner and one of the members of the OncoSTART consortium, the PSCC is proud to contribute to this effort of developing and nurturing an entrepreneurial culture in the oncology field in France and is looking forward enhancing its collaboration with MATWIN.”

Benjamin GAREL
Executive Director



RÉSEAU SATT

Réseau SATT



“I have been working with the MATWIN team for several years. The SATTs propose, according to their own needs, projects to benefit from the scientific, regulatory, and market expertise of their experts’ committees. The coaching offered within the MATWIN accelerator program also allows our academic researchers to improve their skills. Some projects carried out by the SATT were thus able to receive funding, and for all a better visibility of our projects for industrial partners. Finally, the MEET2WIN event is an excellent way to meet the different players in Oncology. It combines a two-day partnering convention with conferences, spotlight sessions for projects, one-to-one prescheduled meetings, and offers concrete opportunities to meet potential partners!”

Hervé ANSANAY
BIOTECH Alliance Manager



www.satt.fr



[@reseau-satt](https://www.linkedin.com/company/reseau-satt)



[@ReseauSATT](https://twitter.com/ReseauSATT)

Sofinnova partners Sofinnova Partners



“MATWIN provides a unique platform in France for networking and collaboration, crucial for the growth and success of early stage companies and a vibrant and supportive ecosystem for founders and entrepreneurs!”

Joël YAO
Partner, Sofinnova Biovelocita



www.sofinnovapartners.com



[@sofinnova-partners](https://www.linkedin.com/company/sofinnova-partners)



[@SofinnovaVC](https://twitter.com/SofinnovaVC)



Takeda



“MATWIN is a unique place for academic, biotech, institutions, VCs and Pharma ecosystem to discover, meet and exchange with entrepreneurs in order to boost the development of the next generation of French start up in Oncology or build innovative projects and partnership. Takeda Oncology in France already leveraged MEET2WIN to create a unique research collaboration with leading oncology centers of excellence.”

Philippe JACQUOT
Country Manager, VP Oncology France



www.takeda.com



[@takeda-pharmaceuticals](https://www.linkedin.com/company/takeda-pharmaceuticals)



[@TakedaPharma](https://twitter.com/TakedaPharma)



[@Takeda-Pharmaceuticals](https://www.youtube.com/channel/UC...)



Unicancer



“Over the last 15 years, our MATWIN subsidiary has demonstrated its effectiveness in the service of oncology and our patients. This platform has presented our French researchers with vast opportunities. MATWIN supports them through high-quality programs and makes it easy for them to meet the very best specialists in oncology and investors. MEET2WIN events, Oncology Upward Investment and programs such as Oncostart are all extraordinary innovation accelerators. Congratulations, and many thanks to the MATWIN team for its tremendous contribution to the transformation of oncology innovation!”

Sophie BEAUPERE
CEO



www.unicancer.fr



[@unicancer](https://www.linkedin.com/company/unicancer)



[@GroupeUnicancer](https://www.x.com/GroupeUnicancer)



[@Unicancer](https://www.facebook.com/Unicancer)



[@groupecancer](https://www.youtube.com/groupecancer)



[@reseau.unicancer](https://www.instagram.com/reseau.unicancer)

THANK YOU

to our partners for their essential support
past and ongoing




THANK YOU to all our ecosystem partners

(non exhaustive list)!



MATWIN

MATURATION & ACCELERATING
TRANSLATION **WITH INDUSTRY**



www.matwin.fr

@MATWIN_Bdx #MEET2WIN

MATWIN - Institut Bergonié
229 Cours de l'Argonne
33076 Bordeaux, France

+33 (0)5 35 54 19 36
contact@matwin.fr